Beyond Bulls & Bears

Monitoring Biotech’s Race for a Vaccine
Equity

Monitoring Biotech’s Race for a Vaccine

Franklin Equity Group's Evan McCulloch and Wendy Lam give their take on when a COVID-19 vaccine could be available for public use.

Biotechnology Innovation During COVID-19
Equity

Biotechnology Innovation During COVID-19

Innovation has always been a key driver for the biotechnology industry. Even in the midst of the COVID-19 pandemic, there is still significant progress in the discovery and development of innovative drugs. Franklin Equity Group’s Evan McCulloch and Wendy Lam are excited about three areas of innovation within biotech that they believe will continue to create value in the long term.

PODCAST: Market Movements: Outlook and Valuations for US Equities
Equity

PODCAST: Market Movements: Outlook and Valuations for US Equities

Franklin Equity Group’s Evan McCulloch, Grant Bowers and Jonathan Curtis take an in-depth look at US equities following the latest market movements. They also share their outlooks for the technology and biotech sectors in particular.

Quick Thoughts: Biotech Progress in Addressing Coronavirus, but It Takes Time
Equity

Quick Thoughts: Biotech Progress in Addressing Coronavirus, but It Takes Time

With the coronavirus creating havoc across the globe, researchers are rushing to find better treatment options and a cure. Our Head of Equities, Stephen Dover, and Portfolio Manager Evan McCulloch outline a few of the efforts the medical and scientific communities are taking to combat the virus.

Assessing Potential US Health Care Reforms Ahead of an Election Year
Equity

Assessing Potential US Health Care Reforms Ahead of an Election Year

Franklin Equity Group’s Evan McCulloch discusses why we might see US legislation on drug pricing before the 2020 US Presidential Election. He also explains why he’s optimistic about the outlook for the biotechnology and pharmaceutical industries.

New Innovation Spurring a Biotech Rejuvenation
Equity

New Innovation Spurring a Biotech Rejuvenation

“We’ve seen medical advancements and breakthroughs in drugs and health care technology reach unprecedented levels in recent years. We foresee this potentially long cycle of innovation persisting.” – Evan McCulloch, Franklin Equity Group

The Politics of Health Care
Equity

The Politics of Health Care

“There have been huge breakthroughs in gene therapy as well as in the area of cancer treatment. Major waves of innovation are a reflection of the exponential leaps in basic research and our understanding of human biology, which are now bearing fruit.” - Evan McCulloch, Franklin Equity Group

3 Reasons Why Investors Should Ignore Political Threats to Biotech
Perspectives

3 Reasons Why Investors Should Ignore Political Threats to Biotech

Drug prices have been thrown back into the headlines after politicians jumped into the fray over the most recent accusations of price gouging. As ...

The Politics—and Potential—of US Biotech
Perspectives

The Politics—and Potential—of US Biotech

The US biotech industry has been in the sickbed so far this year, with many of its indexes in negative territory year to date, even as the overall ...

In the Know: What’s Ailing Biotech?
Equity

In the Know: What’s Ailing Biotech?

In the Know: Professionals at Franklin Templeton Investments offer a quick but insightful update on a pressing investment topic. Concerns about ...

Biotech Boom – or Bubble?
Equity

Biotech Boom – or Bubble?

Currently, there are many exciting products in the pharmaceutical and biotech space producing clinical data that show a meaningful change for patients.

A Biotech and Pharmaceutical RX

A Biotech and Pharmaceutical RX